Dr Nanki is a professor of Division of Rheumatology, Department of Internal Medicine, Toho University, Japan. His research focuses on chemokines, and he has discovered that fractalkine plays roles in the pathogenesis of rheumatoid arthritis (RA). This led to clinical trials of an anti-fractalkine antibody in RA patients, and the antibody’s efficacy was significant. He received the Scientific Award from the Japan College of Rheumatology in 2021, the Novartis Rheumatology Medicine Award from the Japan Rheumatism Foundation in 2018, and the Promotion Award and Young Investigator Award from the Japan College of Rheumatology in 2005 for these research results. Currently, Dr Nanki is analyzing pharyngeal and gut microbiota and senescent cells in order to understand the pathogenesis of rheumatic diseases and develop novel therapies. In his clinical research, Dr Nanki studies therapeutic agents for glucocorticoid-induced osteoporosis and the characteristics of RA complicated by interstitial lung disease.